S&P 500

5.631,22

0,28%

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ARDX

Ardelyx (ARDX)

Ardelyx Inc

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ARDX

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
06/01/2023	22h26	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
06/01/2023	22h25	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
06/01/2023	22h24	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
06/01/2023	22h24	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
29/12/2022	14h25	Dow Jones News	Ardelyx Appeal of Xphozah Denial Granted by FDA	NASDAQ:ARDX	Ardelyx Inc
29/12/2022	13h06	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ARDX	Ardelyx Inc
29/12/2022	13h00	PR Newswire (US)	FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)	NASDAQ:ARDX	Ardelyx Inc
23/12/2022	23h58	PR Newswire (US)	Ardelyx, Inc. Reports Employment Inducement Grants	NASDAQ:ARDX	Ardelyx Inc
19/12/2022	14h20	Dow Jones News	Ardelyx Shares Lower Premarket on Delay in FDA Xphozah Appeal	NASDAQ:ARDX	Ardelyx Inc
17/12/2022	01h51	PR Newswire (US)	Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis	NASDAQ:ARDX	Ardelyx Inc
23/11/2022	22h19	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
23/11/2022	22h17	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
23/11/2022	22h17	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
23/11/2022	22h16	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
23/11/2022	22h15	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
23/11/2022	22h14	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
23/11/2022	22h14	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
22/11/2022	14h00	PR Newswire (US)	Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference	NASDAQ:ARDX	Ardelyx Inc
17/11/2022	22h09	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARDX	Ardelyx Inc
17/11/2022	12h48	Dow Jones News	Ardelyx Shares Soar Premarket After FDA Panel Back Xphozah	NASDAQ:ARDX	Ardelyx Inc
17/11/2022	01h22	Dow Jones News	Ardelyx: FDA Committee Says Benefits of Xphozah Outweigh Risks in Kidney Disease Patients	NASDAQ:ARDX	Ardelyx Inc
17/11/2022	00h29	PR Newswire (US)	Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis	NASDAQ:ARDX	Ardelyx Inc
16/11/2022	17h11	Dow Jones News	Ardelyx Halted as FDA Panel Takes Another Look at Xphozah	NASDAQ:ARDX	Ardelyx Inc
16/11/2022	15h00	PR Newswire (US)	Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis	NASDAQ:ARDX	Ardelyx Inc
04/11/2022	18h39	PR Newswire (US)	National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels	NASDAQ:ARDX	Ardelyx Inc
03/11/2022	21h09	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ARDX	Ardelyx Inc
03/11/2022	21h01	PR Newswire (US)	Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights	NASDAQ:ARDX	Ardelyx Inc
03/11/2022	15h00	PR Newswire (US)	Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial	NASDAQ:ARDX	Ardelyx Inc
02/11/2022	21h01	PR Newswire (US)	Ardelyx, Inc. Reports Employment Inducement Grants	NASDAQ:ARDX	Ardelyx Inc
31/10/2022	13h00	PR Newswire (US)	Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan	NASDAQ:ARDX	Ardelyx Inc